← Back to Search

Anti-arrhythmic

Ablation for Implantable Cardioverter Defibrillators (CEASE-VT Trial)

Phase 3
Waitlist Available
Led By David J Callans, M.D.
Research Sponsored by Population Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 months follow-up
Awards & highlights

CEASE-VT Trial Summary

Implantable Cardioverter Defibrillators (ICDs) provide a shock or pacing therapy to bring back a normal heart beat when a patient experiences a dangerous abnormal heart rhythm such as ventricular tachycardia (VT). ICDs are very successful in bringing back a normal heart beat when VT occurs, but they do not prevent further dangerous heart rhythms from occurring. This study is designed to determine the best way to manage patients who have an ICD and who continue to have episodes of VT. There are two methods for treatment the VT: 1) Ablation, and 2) Medication. An ablation procedure involves placing a flexible catheter (insulated wire) in the groin area and threading it into the heart. After the doctor has located the affected area responsible for the VT, radiofrequency energy is delivered by the power generator through the catheter to the inside of the heart. The radiofrequency energy ablates (burns) a small area of the heart tissue thought to cause the VT. A medication called Amiodarone is an "anti-arrhythmic" prescribed to prevent abnormal heart rhythms from recurring. The purpose of this study is to compare these two different methods for treating VT. Treatment with ablation and amiodarone are both considered the standard of care for patients with VT but they have not been compared directly in a study like this before.

Eligible Conditions
  • Implantable Cardioverter Defibrillators
  • Ventricular Tachycardia

CEASE-VT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 months follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Appropriate ICD Therapy, Slow VT or Sudden Cardiac Death
Secondary outcome measures
Number of Participants With (a) Ablation or Amiodarone Complications, (b) Inappropriate Shocks From ICD, or (c) Need for Concomitant Use of Sotalol, Dofetilide, Azimilide or Class 1 Antiarrhythmic Agents in Either Arm of the Trial.
Quality of Life Score

CEASE-VT Trial Design

2Treatment groups
Active Control
Group I: AblationActive Control1 Intervention
Catheter based radiofrequency ablation for ischemic ventricular tachycardia
Group II: AmiodaroneActive Control1 Intervention
amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study.

Find a Location

Who is running the clinical trial?

Population Health Research InstituteLead Sponsor
157 Previous Clinical Trials
686,635 Total Patients Enrolled
Hamilton Health Sciences CorporationOTHER
369 Previous Clinical Trials
300,469 Total Patients Enrolled
Abbott Medical DevicesIndustry Sponsor
644 Previous Clinical Trials
406,074 Total Patients Enrolled
~1 spots leftby Jun 2025